Back to results
US 10,702,600 B1Granted
Betacoronavirus mRNA vaccine
AssigneeModernaTX, Inc.
InventorsGiuseppe Ciaramella, Sunny Himansu
Life of this patent
Estimating the term…
Abstract
The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Claims26
A composition, comprising:
- a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein subunit formulated in a lipid nanoparticle.
A composition, comprising:
- a messenger ribonucleic acid (mRNA) comprising a 5′ untranslated region (UTR), an open reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein subunit, a 3′ UTR, and a poly(A) tail, formulated in a lipid nanoparticle that comprises 20-60% ionizable cationic lipid, 5-25% neutral lipid, 25-55% cholesterol, and 0.5-15% PEG-modified lipid.
A composition, comprising:
- a messenger ribonucleic acid (mRNA) comprising a 5′ cap analog, a 5′ untranslated region (UTR), an open reading frame encoding a betacoronavirus (BetaCoV) S protein, a 3′ UTR, and a poly(A) tail, formulated in a lipid nanoparticle that comprises 20-60% ionizable cationic lipid, 5-25% DSPC, 25-55% cholesterol, and 0.5-15% PEG-DMG, wherein the ionizable cationic lipid has the structure of Compound 25, and wherein at least 80% of the uracil in the open reading frame has a 1-methylpseudouridine modification.
A lipid nanoparticle, comprising:
- a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein subunit;
- wherein the lipid nanoparticle comprises 20-60% ionizable cationic lipid, 5-25% neutral lipid, 25-55% cholesterol, and 0.5-15% PEG-modified lipid.
Dependencies are inferred from the claim text.